Project Grant R41AR086050
Award Date 9/19/25
Completion Date 8/31/26
Dollars Obligated $305K
Funding Federal Agency
Awarding Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Raleigh, NC 27613, USA
Similar Awards
- This federal Project Grant award for $306,825.00 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The funding supports the development of RG0401, an ex vivo autologous CD34+ hematopoietic progenitor and stem cell-based gene therapy by Rheumagen, Inc. to treat refractory rheumatoid arthritis (RA). The therapy aims to replace the DRB1*04:01 RA-inducing allele with a resistant allele to...
- This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $297,327 to Navega Therapeutics, Inc. to reformulate its NT-Z001 gene therapy and evaluate its efficacy for treating rheumatoid arthritis (RA) through localized joint injections. The goal is to develop a novel, non-addictive approach to managing chronic pain in RA patients by...
- This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $295,924 to Biotherapeutics, Inc. to advance the development of a novel oral, first-in-class therapeutic for the treatment of rheumatoid arthritis (RA). The project aims to conduct pharmacokinetic and safety studies, characterize the effects of the lead compound on human fibroblast-like...
- This $187,938 Project Grant was awarded on January 9, 2025 by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) to The Johns Hopkins University to support research into the origin of anti-citrullinated protein antibodies (ACPAs) in rheumatoid arthritis (RA). The research aims to test the hypothesis that ACPAs may arise from antibodies targeting structurally similar carbamylated proteins during the affinity maturation process. If...
- This Project Grant award of $3,192,404 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) supports research at Duke University focused on understanding and managing immune system responses to recombinant adeno-associated virus (AAV) gene therapy vectors. The award aims to develop preclinical models and immunomodulatory strategies to address complex adverse reactions, such as cytokine release, thrombotic microangiopathy, and acute...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $459,250 to Cedars-Sinai Medical Center to conduct research on the role of synoviocyte and endothelial cell interactions in rheumatoid arthritis. The research aims to validate a pathway connecting fibroblast-like synoviocyte (FLS) transmigration with endothelial cell-mediated inflammation, and assess the impact of a specific FLS gene on...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a division of the National Institutes of Health, awarded a $527,760 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to The Regents of the University of California, San Francisco (UCSF) on July 1, 2025. The grant will support research to identify the early mechanistic events that break T cell tolerance and contribute to the development of rheumatoid arthritis...
- This Project Grant award of $139,895.00 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) will support research into the link between inflammatory arthritis and the development of cardiovascular disease. The key objectives are to investigate whether "trained immunity" - the phenomenon where innate immune cells become reprogrammed to respond more efficiently to a...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), awarded a $314,363 Project Grant to Biotherapeutics, Inc., a clinical-stage biopharmaceutical company based in Blacksburg, VA. The grant supports the research and development of a novel oral small molecule therapeutic candidate for the treatment of systemic lupus erythematosus (SLE), an autoimmune disease affecting 1.5 million Americans....
- This $300,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of a GMP-compliant E. coli dihydrofolate reductase (EDHFR) vector. This vector will be used to monitor the biodistribution and trafficking of investigational chimeric antigen receptor (CAR) T cell therapies through positron emission tomography (PET) imaging. The goals are to provide a...